92 Recruiting Studies Using Obinutuzumab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Obinutuzumab
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
📍 Stanford University Medical Center (Data collection only) — Stanford, California
Chronic Lymphocytic Leukemia (CLL)
View Study & Checklist ➔A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
📍 UC San Diego Moores Cancer Center — La Jolla, California
Lymphoma
View Study & Checklist ➔Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
📍 UCLA Hematologyoncology — Los Angeles, California
Mature B-Cell Malignancies
View Study & Checklist ➔Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
📍 Huntsman Cancer Institute at University of Uta — Salt Lake City, Utah
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
View Study & Checklist ➔A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
📍 Pinnacle Research Group — Anniston, Alabama
Systemic Lupus Erythematosus
View Study & Checklist ➔Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
📍 Research Site — Los Angeles, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Diffuse Large B-cell Lymphoma
View Study & Checklist ➔Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
📍 Alaska Breast Care and Surgery LLC — Anchorage, Alaska
Grade 1 Follicular Lymphoma
View Study & Checklist ➔A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
📍 Lucile Packard Children's Hospital - Stanford — Palo Alto, California
Childhood Idiopathic Nephrotic Syndrome
View Study & Checklist ➔Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Follicular Lymphoma
View Study & Checklist ➔Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
📍 Weill Cornell Medicine — New York, New York
Mantle Cell Lymphoma
View Study & Checklist ➔Safe Accelerated Venetoclax Escalation in CLL
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
📍 University of Alabama at Birmingham Medical Center — Birmingham, Alabama
Lupus Nephritis
View Study & Checklist ➔Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
📍 Research Site — Goodyear, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Lymphoma
View Study & Checklist ➔Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
📍 Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut
Chronic Lymphocytic Leukemia (CLL)
View Study & Checklist ➔A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
📍 University of California San Francisco - Fresno Center for Medical Education and Research — Clovis, California
B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
📍 Massachusetts General Hospital — Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
📍 University of Michigan — Ann Arbor, Michigan
Non-Hodgkin's Lymphoma
View Study & Checklist ➔A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
📍 Yale University — New Haven, Connecticut
Hairy Cell Leukemia
View Study & Checklist ➔Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
📍 Alaska Oncology and Hematology, Llc — Anchorage, Alaska
CLL
View Study & Checklist ➔Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
📍 UCSF Fresno /ID# 264712 — Fresno, California
Follicular Lymphoma (FL)
View Study & Checklist ➔Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
📍 Emory University — Atlanta, Georgia
B-Cell Lymphoma, Unspecified
View Study & Checklist ➔A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
📍 City of Hope Medical Center — Pasadena, California
Lymphoma, Non-Hodgkin
View Study & Checklist ➔A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 City of Hope /ID# 253904 — Duarte, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
📍 UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program — San Francisco, California
Non-Hodgkin Lymphoma
View Study & Checklist ➔A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
📍 Ucsf Fresno University of California San Francisco Fresno — Fresno, California
Relapsed/Refractory Follicular Lymphoma
View Study & Checklist ➔Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Follicular Lymphoma
View Study & Checklist ➔Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
View Study & Checklist ➔AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
📍 Artiva Investigational Site Birmingham — Birmingham, Alabama
Lupus Nephritis - WHO Class III
View Study & Checklist ➔Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
CCND1 Positive
View Study & Checklist ➔Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
📍 Kaiser Permanente - San Francisco Medical Center — San Francisco, California
Primary Membranous Nephropathy
View Study & Checklist ➔A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
📍 Dana Farber Cancer Institute (Data Collection and Specimen Analysis) — Boston, Massachusetts
Mantle Cell Lymphoma
View Study & Checklist ➔A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
📍 Local Institution - 109 — Scottsdale, Arizona
Lymphoma, Non-Hodgkin
View Study & Checklist ➔A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
📍 Memorial Sloan Kettering Basking Ridge (All protocol activities) — Basking Ridge, New Jersey
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 Research Site — Tucson, Arizona
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
View Study & Checklist ➔Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
📍 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
Non-Hodgkin's Lymphoma
View Study & Checklist ➔Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
📍 Weill Cornell Medicine/NewYork-Presberteryian Hospital — New York, New York
Leukemia, Lymphocytic, Chronic, B-Cell
View Study & Checklist ➔Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
📍 University of California, San Francisco (UCSF) Fresno — Fresno, California
Ann Arbor Stage II Follicular Lymphoma
View Study & Checklist ➔A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 Norton Cancer Institute — Louisville, Kentucky
Leukemia, Lymphocytic, Chronic, B-Cell
View Study & Checklist ➔Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
📍 Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
Chronic Lymphocytic Leukemia
View Study & Checklist ➔GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
📍 Massachusetts General Hospital — Boston, Massachusetts
Lymphoma
View Study & Checklist ➔TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
📍 Rhode Island Hospital — Providence, Rhode Island
Diffuse Large B Cell Lymphoma
View Study & Checklist ➔A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
📍 UT MD Anderson — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔CAR-T Followed by Bispecific Antibodies
📍 University of Nebraska Medical Center — Omaha, Nebraska
Large B-cell Lymphoma
View Study & Checklist ➔Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
📍 University of California, Davis — Davis, California
Mantle Cell Lymphoma
View Study & Checklist ➔Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
📍 Arizona Oncology - Tucson - Rudasill /ID# 267552 — Tucson, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
📍 BRCR Medical Center — Plantation, Florida
Mature B-cell Malignancies
View Study & Checklist ➔Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
Blastoid Variant Mantle Cell Lymphoma
View Study & Checklist ➔A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
📍 Alta Bates Summit Medical Center — Berkeley, California
Lymphoma
View Study & Checklist ➔Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Recurrent Mantle Cell Lymphoma
View Study & Checklist ➔Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
📍 M D Anderson Cancer Center — Houston, Texas
Leukemia
View Study & Checklist ➔A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
📍 MD Anderson Cancer Center — Houston, Texas
B Cell Lymphoma
View Study & Checklist ➔Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
📍 MD Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
Mantle Cell Lymphoma
View Study & Checklist ➔Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
📍 New England Cancer Specialists — Scarborough, Maine
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
📍 Uci Health Laguna Hills — Laguna Hills, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
📍 Children's Hospital of Alabama — Birmingham, Alabama
Mature B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
📍 OHSU Knight Cancer Institute — Portland, Oregon
Mantle Cell Lymphoma
View Study & Checklist ➔Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
📍 Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute — Cleveland, Ohio
Relapsed CLL
View Study & Checklist ➔Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
📍 New York Medical College — Valhalla, New York
Non-Hodgkin Lymphoma
View Study & Checklist ➔Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
📍 Northwestern University — Evanston, Illinois
Chronic Lymphocytic Leukemia (CLL)
View Study & Checklist ➔A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Hairy Cell Leukemia
View Study & Checklist ➔A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
📍 Loma Linda University health — Loma Linda, California
Lupus Nephritis
View Study & Checklist ➔A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
📍 Mayo Clinic Phoenix — Phoenix, Arizona
B-cell Malignancy
View Study & Checklist ➔Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
📍 City of Hope Medical Center — Duarte, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
📍 Banner University Medical Center - Tucson — Tucson, Arizona
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements
View Study & Checklist ➔Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Grade 1 Follicular Lymphoma
View Study & Checklist ➔LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
📍 University of Cincinnati Medical Center — Cincinnati, Ohio
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
View Study & Checklist ➔Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
📍 Massachusetts General Hospital — Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Primary Central Nervous System Lymphoma
View Study & Checklist ➔Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
📍 Rocky Mountain Cancer Centers — Aurora, Colorado
B-cell Lymphoma
View Study & Checklist ➔Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
📍 Moores Cancer Center at UC San Diego /ID# 230157 — La Jolla, California
Chronic Lymphocytic Leukemia (CLL)
View Study & Checklist ➔Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Diffuse Large B Cell Lymphoma (DLBCL)
View Study & Checklist ➔Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
📍 Winship Cancer Institute at Emory University — Atlanta, Georgia
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Lymphoma
View Study & Checklist ➔Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
📍 Mayo Clinic — Rochester, Minnesota
Fibrillary Glomerulonephritis
View Study & Checklist ➔Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
📍 OHSU Knight Cancer Institute — Portland, Oregon
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
📍 HonorHealth Research Institute — Scottsdale, Arizona
Cancer
View Study & Checklist ➔A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
📍 Alaska Oncology & Hematology, LLC — Anchorage, Alaska
B-Cell Non-Hodgkins Lymphoma
View Study & Checklist ➔Avo In R/R And Previously Untreated MCL
📍 University of Chicago Medical Center — Chicago, Illinois
Mantle Cell Lymphoma
View Study & Checklist ➔